Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma
Xingliang TanDong ChenShengjie GuoYanjun WangYuantao ZouZhiming WuFangjian ZhouZike QinZhuowei LiuYun CaoChunhua LinGangjun YuanKai Yao
6
Citation
48
Reference
10
Related Paper
Citation Trend
Abstract:
Background: Lymph node metastasis is the most unfavorable prognostic factor of penile squamous cell carcinoma (PSCC). However, patients with the same lymph node status have different outcomes, and molecular classifiers for precise prognostic assessments are lacking. Methods: Comprehensive genomic profiling and high-content proliferation screening were performed in eight PSCC and normal tissue pairs and in cell lines. BCL2A1 and AIM2 were selected and further evaluated by qPCR and Western blot. The clinical relevance and prognostic value of the target genes were validated via immunohistochemistry in a cohort of 220 PSCC patients with a defined pN stage. Finally, the biological functions and molecular mechanisms of BCL2A1 and AIM2 were investigated in vitro and in vivo. Results: BCL2A1 and AIM2 were both upregulated in PSCC tissues and associated mostly with cell proliferation. Staining for either BCL2A1 or AIM2 revealed that both are correlated with pN status, extranodal extension, clinical stage and cancer-specific survival (CSS). Compared to patients who are single-positive or double-negative for BCL2A1 and AIM2, those overexpressing both genes had a higher risk of tumor progression and the poorest survival in the pN0 (5-year CSS: 63.3% vs. 94.9% and 100.0%, respectively, p = 0.000) and pN+ subsets (5-year CSS: 24.1% vs. 45.7% and 55.1%, respectively, p = 0.035). Molecular biofunction and mechanistic studies demonstrated that BCL2A1 and AIM2 knockdown inhibited tumorigenesis via the AIM2/NF-κB/BCL2A1/MAPK/c-Myc signaling pathway. Conclusions: BCL2A1 and AIM2 promote PSCC progression. Integrating BCL2A1 and AIM2 as novel molecular classifiers with pN stage provides additional information for the prognosis and treatment of PSCC patients.Keywords:
Risk Stratification
Risk Stratification
Stratification (seeds)
Value (mathematics)
Cite
Citations (0)
Risk Stratification
Stratification (seeds)
Cite
Citations (12)
Risk Stratification
ST elevation
Cite
Citations (0)
Risk Stratification
Stratification (seeds)
Sudden Death
Cite
Citations (0)
Risk Stratification
Stratification (seeds)
Modalities
Cite
Citations (0)
This chapter contains sections titled: History: role in diagnosis and risk stratification Diagnostic value of symptoms at presentation: angina, anginal equivalents, and atypical presentations Risk stratification: presenting symptoms and other aspects of the history Physical examination: role in diagnosis and risk stratification ECG: role in diagnosis and risk stratification Integration of clinical and ECG data into risk stratification algorithms Conclusions References
Risk Stratification
Stratification (seeds)
Clinical Diagnosis
Presentation (obstetrics)
Medical History
Unstable angina
Clinical history
Cite
Citations (0)
Risk stratification aims to have enough patient-centric data to have an informed discussion with the patient, with the goal of "doing the right procedure for the right patient at the right time." The purpose of this chapter is to help clinicians identify the "right patient and right time" for a transcatheter aortic valve replacement (TAVR) procedure, which will require knowledge of the strength of relevant cardiovascular and noncardiovascular predictors and then application of this data to the patient's expectations and goals. We will integrate this discussion with the strengths and applicability of popular risk-scoring models.
Risk Stratification
Stratification (seeds)
Cite
Citations (0)
Fatal complications of noncardiac surgery most often are cardiovascular. This has led to the development of preoperative cardiac risk-assessment
Risk Stratification
Stratification (seeds)
Cite
Citations (0)
b r t w u r t i c As with other cardiovascular diseases, advances in our understanding of the pathophysiology of acute coronary syndrome (ACS) have resulted in the use of new biomarkers (measurable plasma molecules) that reflect the different mechanisms that underlie the condition. These biomarkers are valuable tools that are increasingly used not only for early diagnosis but for shortand long-term prognostic stratification. A wide range of biomarkers are now available in ACS, including those that reflect vascular inflammation due to atherosclerotic disease (high-sensitivity C-reactive protein [CRP]), markers of protease activity associated with progression of atherosclerosis and plaque destabilization (cystatin C), and those indicating myocardial injury (troponin and ST2), renal damage (cystatin C, NGAL, glomerular filtration rate), or ventricular dysfunction (neurohormonal peptides
Risk Stratification
Stratification (seeds)
Cite
Citations (0)
Risk Stratification
Stratification (seeds)
Cite
Citations (0)